X4 Pharmaceuticals Reports Q4 Revenue of $2.6M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy XFOR?
Reports Q4 revenue $2.6M, consensus $1.73M. "Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "We have sharpened our operational focus and implemented targeted initiatives to drive continued progress in 4WARD with enrollment on track for completion in the third quarter of this year. Additionally, we were pleased to receive the positive opinion from the European Medicines Agency recommending the potential European approval of mavorixafor in WHIM syndrome, which would be the first and only therapy in Europe to treat this devastating condition."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XFOR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XFOR
Wall Street analysts forecast XFOR stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.290
Low
7.00
Averages
57.75
High
120.00
Current: 4.290
Low
7.00
Averages
57.75
High
120.00
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
X4 Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.04, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Performance: The company generated $2.71 million in revenue for the quarter, a significant 90.6% year-over-year decline, yet it exceeded market expectations by $0.88 million, suggesting some resilience in sales amidst challenges.
- Cash Position: As of March 31, 2026, X4's cash position stood at $233.7 million, ensuring sufficient funding for future R&D and operations, which bolsters market confidence in its ongoing viability.
- Market Outlook: Presenting at the Guggenheim Securities Biotech Summit, X4 Pharmaceuticals highlighted its funded path to FDA approval, demonstrating its proactive approach to navigating challenges while seeking growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Completes EU Approval for XOLREMDI®
- Clinical Trial Progress: X4 Pharmaceuticals is on track to complete enrollment for its pivotal 4WARD Phase 3 trial by Q3 2026, with over 110 active clinical trial sites globally, enhancing patient recruitment and regulatory alignment, demonstrating the company's ongoing commitment to treating rare hematologic disorders.
- Product Approval: The European Commission has granted marketing authorization for XOLREMDI® (Mavorixafor) for the treatment of patients with WHIM syndrome, making it the only authorized treatment in this area, which is expected to generate up to €226 million in milestone payments and double-digit royalties on future sales.
- Financial Performance: As of March 31, 2026, the company reported a cash position of $233.7 million, with revenue declining to $2.7 million year-over-year; however, through reduced R&D and administrative expenses, net loss decreased to $20.2 million, reflecting positive cost control measures.
- Market Outlook: Mavorixafor, as a CXCR4 antagonist, has the potential to improve the quality of life for chronic neutropenia patients, which is expected to drive long-term growth for the company in the rare hematology market, particularly through its commercialization partnership with Norgine.
See More
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On March 31, 2026, X4 Pharmaceuticals granted 32,000 stock options to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting and retaining talent while enhancing the company's competitive edge in rare hematology diseases.
- Option Details: The options have an exercise price of $4.13 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule, reflecting the company's commitment to long-term employee contributions.
- Clinical Trial Progress: X4 is conducting a pivotal global Phase 3 trial evaluating its CXCR4 antagonist mavorixafor for chronic neutropenic disorders, with the FDA granting Fast Track designation, indicating strong market anticipation for the drug.
- Company Vision: Focused on developing innovative therapies to improve the lives of patients with rare hematology diseases, X4 leverages expertise in immune system disorders and CXCR4 biology to address significant unmet medical needs and drive long-term growth.
See More
X4 Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.13, indicating a positive trend in improving profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $2.57 million, a 79.7% year-over-year increase, surpassing market expectations by $0.84 million, suggesting strong product demand and enhanced market acceptance, potentially laying the groundwork for future growth.
- Stock Price Reaction: Following the earnings release, X4 Pharmaceuticals' shares rose by 4% in after-hours trading, reflecting a positive investor response to the company's performance, which may bolster market confidence and attract more investor interest.
- Industry Outlook: X4 Pharmaceuticals presented its future outlook at the Guggenheim Securities Biotech Summit, emphasizing its funded path to FDA approval, indicating the company's strategic positioning and potential growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Receives Positive EMA Opinion for Mavorixafor
- Regulatory Progress: X4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for mavorixafor to treat WHIM syndrome, with a decision from the European Commission expected in Q2 2026, potentially opening significant market opportunities for the company.
- Clinical Trial Results: This positive opinion is supported by favorable outcomes from a pivotal Phase 3 trial assessing the efficacy and safety of XOLREMDI in patients aged 12 and older with WHIM syndrome, demonstrating strong clinical effectiveness and enhancing the drug's market outlook.
- Commercial Partnership Agreement: In January 2025, X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand following regulatory approvals, potentially generating up to $226 million in regulatory and commercial milestone payments for X4.
- Future Revenue Potential: X4 is also eligible for escalating double-digit royalties of up to the mid-twenties percentage on future net sales, providing a stable revenue stream and enhancing its competitive position in the global market.
See More
X4 Pharmaceuticals Receives Positive Opinion for WHIM Syndrome Therapy in EU
- Regulatory Milestone: X4 Pharmaceuticals' mavorixafor has received a positive opinion from the EMA's CHMP, potentially becoming the first and only therapy for WHIM syndrome in the EU, addressing a significant unmet medical need for patients with this ultra-rare disease.
- Clinical Trial Success: The 4WHIM trial demonstrated that mavorixafor significantly increased absolute neutrophil counts (ANC) and absolute lymphocyte counts (ALC), with threshold time improvements compared to placebo and a 60% reduction in infection rates, showcasing its remarkable efficacy.
- Commercial Partnership Agreement: X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand, allowing X4 to receive up to €226 million in milestone payments and double-digit royalties on future sales, enhancing the company's revenue potential.
- Market Access Strategy: X4 plans to collaborate with Norgine to ensure timely patient access to this critical treatment following final approval, further solidifying its market position in the rare disease sector.
See More
X4 Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.04, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Performance: The company generated $2.71 million in revenue for the quarter, a significant 90.6% year-over-year decline, yet it exceeded market expectations by $0.88 million, suggesting some resilience in sales amidst challenges.
- Cash Position: As of March 31, 2026, X4's cash position stood at $233.7 million, ensuring sufficient funding for future R&D and operations, which bolsters market confidence in its ongoing viability.
- Market Outlook: Presenting at the Guggenheim Securities Biotech Summit, X4 Pharmaceuticals highlighted its funded path to FDA approval, demonstrating its proactive approach to navigating challenges while seeking growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Completes EU Approval for XOLREMDI®
- Clinical Trial Progress: X4 Pharmaceuticals is on track to complete enrollment for its pivotal 4WARD Phase 3 trial by Q3 2026, with over 110 active clinical trial sites globally, enhancing patient recruitment and regulatory alignment, demonstrating the company's ongoing commitment to treating rare hematologic disorders.
- Product Approval: The European Commission has granted marketing authorization for XOLREMDI® (Mavorixafor) for the treatment of patients with WHIM syndrome, making it the only authorized treatment in this area, which is expected to generate up to €226 million in milestone payments and double-digit royalties on future sales.
- Financial Performance: As of March 31, 2026, the company reported a cash position of $233.7 million, with revenue declining to $2.7 million year-over-year; however, through reduced R&D and administrative expenses, net loss decreased to $20.2 million, reflecting positive cost control measures.
- Market Outlook: Mavorixafor, as a CXCR4 antagonist, has the potential to improve the quality of life for chronic neutropenia patients, which is expected to drive long-term growth for the company in the rare hematology market, particularly through its commercialization partnership with Norgine.
See More
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On March 31, 2026, X4 Pharmaceuticals granted 32,000 stock options to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting and retaining talent while enhancing the company's competitive edge in rare hematology diseases.
- Option Details: The options have an exercise price of $4.13 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule, reflecting the company's commitment to long-term employee contributions.
- Clinical Trial Progress: X4 is conducting a pivotal global Phase 3 trial evaluating its CXCR4 antagonist mavorixafor for chronic neutropenic disorders, with the FDA granting Fast Track designation, indicating strong market anticipation for the drug.
- Company Vision: Focused on developing innovative therapies to improve the lives of patients with rare hematology diseases, X4 leverages expertise in immune system disorders and CXCR4 biology to address significant unmet medical needs and drive long-term growth.
See More
X4 Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.13, indicating a positive trend in improving profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $2.57 million, a 79.7% year-over-year increase, surpassing market expectations by $0.84 million, suggesting strong product demand and enhanced market acceptance, potentially laying the groundwork for future growth.
- Stock Price Reaction: Following the earnings release, X4 Pharmaceuticals' shares rose by 4% in after-hours trading, reflecting a positive investor response to the company's performance, which may bolster market confidence and attract more investor interest.
- Industry Outlook: X4 Pharmaceuticals presented its future outlook at the Guggenheim Securities Biotech Summit, emphasizing its funded path to FDA approval, indicating the company's strategic positioning and potential growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Receives Positive EMA Opinion for Mavorixafor
- Regulatory Progress: X4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for mavorixafor to treat WHIM syndrome, with a decision from the European Commission expected in Q2 2026, potentially opening significant market opportunities for the company.
- Clinical Trial Results: This positive opinion is supported by favorable outcomes from a pivotal Phase 3 trial assessing the efficacy and safety of XOLREMDI in patients aged 12 and older with WHIM syndrome, demonstrating strong clinical effectiveness and enhancing the drug's market outlook.
- Commercial Partnership Agreement: In January 2025, X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand following regulatory approvals, potentially generating up to $226 million in regulatory and commercial milestone payments for X4.
- Future Revenue Potential: X4 is also eligible for escalating double-digit royalties of up to the mid-twenties percentage on future net sales, providing a stable revenue stream and enhancing its competitive position in the global market.
See More
X4 Pharmaceuticals Receives Positive Opinion for WHIM Syndrome Therapy in EU
- Regulatory Milestone: X4 Pharmaceuticals' mavorixafor has received a positive opinion from the EMA's CHMP, potentially becoming the first and only therapy for WHIM syndrome in the EU, addressing a significant unmet medical need for patients with this ultra-rare disease.
- Clinical Trial Success: The 4WHIM trial demonstrated that mavorixafor significantly increased absolute neutrophil counts (ANC) and absolute lymphocyte counts (ALC), with threshold time improvements compared to placebo and a 60% reduction in infection rates, showcasing its remarkable efficacy.
- Commercial Partnership Agreement: X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand, allowing X4 to receive up to €226 million in milestone payments and double-digit royalties on future sales, enhancing the company's revenue potential.
- Market Access Strategy: X4 plans to collaborate with Norgine to ensure timely patient access to this critical treatment following final approval, further solidifying its market position in the rare disease sector.
See More
